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Edited by Judit Ova´diAbstract Cyclooxygenase-2 (COX-2) catalyzes the rate-limit-
ing step in the prostanoid biosynthesis pathway, converting ara-
chidonic acid into prostaglandin H2. COX-2 exists as 72 and
74 kDa glycoforms, the latter resulting from an additional oligo-
saccharide chain at residue Asn580. In this study, Asn580 was mu-
tated to determine the biological signiﬁcance of this variable
glycosylation. COS-1 cells transfected with the mutant gene
were unable to express the 74 kDa glycoform and were found
to accumulate more COX-2 protein and have ﬁve times greater
COX-2 activity than cells expressing both glycoforms. Thus,
COX-2 turnover appears to depend upon glycosylation of the
72 kDa glycoform.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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mutagenesis1. Introduction
Prostanoids, which consist of prostaglandins and thrombox-
anes, represent a family of lipid-soluble, bioactive compounds
which have been associated with a multitude of physiological
processes and pathophysiological conditions that include:
platelet aggregation, bone metabolism, ovulation, inﬂamma-
tion, ischemia, and various cancers (reviewed in [1]). The
rate-limiting step in the prostanoid synthesis pathway is cata-
lyzed by the integral membrane protein cyclooxygenase
(COX), also known as prostaglandin H2 (PGH2) synthase
[2,3], which is localized to the endoplasmic reticulum (ER)
and nuclear envelope [4]. COX is bifunctional, converting ara-
chidonic acid (AA), an omega-6 fatty acid, to the precursorAbbreviations: COX, cyclooxygenase; AA, arachidonic acid; PGG2,
prostaglandin G2; PGH2, prostaglandin H2; kDa, kilodalton; DMEM,
Dulbecco’s Modiﬁed Eagle’s Medium; FBS, fetal bovine serum; PBS,
phosphate buﬀered saline; SDS, sodium dodecyl sulfate; ELISA,
enzyme-linked immunosorbent assay; OA, octanoic acid; PGE2,
prostaglandin E2; PI3K, phosphatidylinositol 3-kinase; NSAIDs,
non-steroidal anti-inﬂammatory drugs; ER, endoplasmic reticulum
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to the precursor PGH2 via cyclooxygenase and peroxidase
activities, respectively. Three isoforms of COX have been
found – the constitutively expressed COX-1 [5–7]; COX-2,
which can be inducible or constitutive, depending on the tissue
[1,8–10]; and the constitutively expressed COX-3, which is be-
lieved to be a splice variant of COX-1 [11]. Although COX-1 is
considered the housekeeping enzyme expressed in nearly all tis-
sues, COX-2 is generally perceived to be involved in patholog-
ical conditions, such as inﬂammation and cancer [1,12,13]. In
particular, we have found that the presence of AA in human
prostate cancer cells up-regulates COX-2 mRNA and protein
expression [14,15] – speciﬁcally, the 72 kDa glycoform [16].
However, COX-2 is also involved with normal physiological
processes such as neurotransmission and synaptic activity
[17,18], maintaining normal renal functions [19], providing
vascular protection [20], regulating cerebral blood ﬂow [21],
and facilitating pregnancy [22].
The COX-2 sequence contains ﬁve potential N-glycosylation
sites, three of which are always glycosylated, one (Asn580 in
human and mouse) that is glycosylated 650% of the time,
and one that is never glycosylated [23]. The carbohydrate moi-
eties at each site are believed to be high-mannose chains
[24,25]. The variability of glycosylation at Asn580 leads to the
production of two distinct glycoforms of 72 and 74 kDa. Pre-
vious studies have examined this variable glycosylation at the
Asn580 site, but none were able to determine the purpose or
biological signiﬁcance of the two COX-2 glycoforms [23,25].
In this study, we strove to determine the purpose of glycosyl-
ation at Asn580 – speciﬁcally, if and how this additional glyco-
sylation aﬀects COX-2 activity. We found that glycosylation at
Asn580 does indeed aﬀect total COX-2 activity by controlling
the enzyme’s turnover.2. Materials and methods
2.1. Materials
The human COX-2 cDNA in plasmid pcDNA3 was generously pro-
vided by Dr. Timothy Hla from the University of Connecticut, USA.
The COS-1 cell line was obtained from the UCSF Cell Culture Facility
(San Francisco, CA, USA). QIAprep Spin Miniprep kit, HiSpeed
Plasmid Maxi kit, and the primers used for site-directed mutagenesis
(50-TCATTAAAACAGTCACCATCCAGGCAAGTTCTTCCCGCTC-
3 0 and 5 0-GAGCGGGAAGAACTTGCCTGGATGGTGACTGTTT-
TAATGA-3 0) were purchased from QIAGEN (Valencia, CA, USA).
The PfuUltra HF DNA polymerase was purchased from Stratagene
(La Jolla, CA, USA). The transfection reagent FuGENE 6 was pur-
chased from Roche Applied Science (Indianapolis, IN, USA). One
Shot TOP10 Competent Escherichia coli cells, pre-made 4–12% Bis–European Biochemical Societies.
AB
Fig. 1. COX-2 glycoforms expressed from wild-type and mutant
COX-2 genes. (A) Whole cell lysates were analyzed via Western
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Invitrogen (Carlsbad, CA, USA). The anti-human COX-2 polyclonal
antibody, the prostaglandin E2 (PGE2) EIA kit – Monoclonal and per-
oxide-free AA were purchased from Cayman Chemical (Ann Arbor,
MI, USA). Octanoic acid was purchased from Sigma.
2.2. Site-directed mutagenesis
DNA primers were designed to convert the Asn residue at site 580 in
the human COX-2 sequence to a Gln residue. The mutagenesis reaction
contained pcDNA3-COX-2, sense and antisense DNA primers, dNTP
mix, and Pfu Ultra HF DNA polymerase. The reaction was incubated
at 95 C for 30 s. This was followed by 16 cycles of: 95 C for 30 s, 55 C
for 1 min, and 68 C for 7 min, 30 s. The restriction enzyme DpnI was
then added to the reaction to cleave up the original plasmid, leaving in-
tact only plasmids containing the mutant COX-2 gene.
2.3. Transfection of COS-1 cells
One Shot TOP10 Competent E. coli cells were used to produce large
quantities of plasmid containing either the wild-type or mutant COX-2
gene. Plasmids were isolated and puriﬁed using the HiSpeed Plasmid
Maxi kit according to the manufacturer’s instructions. COS-1 cells
were grown on 6-well plates in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM), 1% fetal bovine serum (FBS) media at 37 C. FuGENE 6
reagent was used to transiently transfect cells with either the wild-type
or mutant COX-2 gene according to the manufacturer’s instructions.
Cells were incubated at 37 C for 4–5 h in the presence of the FuGENE
6/COX-2 DNA complex. Media was replaced with DMEM, 10% FBS,
4 mM L-glutamine, and antibiotics, and the cells continued their incu-
bation.
2.4. Western blot analyses
Transfected and non-transfected COS-1 cells growing on 6-well
plates were washed with ice-cold phosphate buﬀered saline and then
lysed. The whole cell lysates were sonicated brieﬂy and subjected to
centrifugation at 14,000 · g for 5 min to remove cytoskeletal struc-
tures. Protein concentrations were determined, and cell lysate samples
underwent gel electrophoresis using either 4–12% Bis–Tris NuPAGE
gels or 16 cm, 7% sodium dodecyl sulfate (SDS)-polyacrylamide gels.
After electrophoresis, proteins were transferred to nitrocellulose and
immunostained for COX-2 protein using anti-human COX-2 poly-
clonal antibody. The membrane was also immunostained for the
housekeeping gene b-actin. Bound antibody was detected using chemi-
luminescence and ﬁlm. Densitometry analyses were then carried out
using the software UNSCAN-IT by Silk Scientiﬁc.
2.5. ELISA for measuring PGE2 levels
Transfected and non-transfected COS-1 cells growing on 6-well
plates were treated with 5 lg/ml of either AA or octanoic acid (OA)
for 2 h at 37 C, as previously described [16]. Media samples were then
collected and analyzed for the presence of the downstream product
PGE2 using a PGE2 EIA kit – Monoclonal. Dilutions of the media
samples were prepared in a 96-well plate and were treated and analyzed
according to the manufacturer’s instructions.
2.6. Statistical analysis
Using Instat 3 software, densitometry data were subjected to One-
way Analysis of variance (ANOVA). Enzyme-linked immunosorbent
assay (ELISA) results were also subjected to ANOVA followed by
the Student–Newman–Keuls Multiple Comparisons Test.blotting after transient transfection of COS-1 cells with either the wild-
type or Asn580-mutant COX-2 gene. Each lane was loaded with 15 lg
of protein. Blot shown represents a sample size of 10 (n = 10). Graph
depicts densitometry values of COX-2 bands normalized to b-actin
levels. ***P < 0.0001 compared to WT 72 kDa (Student-Newman-
Keuls Multipule Comparisons Test); n = 3. (B) Whole cell lysates were
analyzed 3, 4, and 5 days after transient transfection with the wild-type
or mutant COX-2 gene. Each lane was loaded with 15 lg of protein.
Blot shown is representative of duplicate samples (n = 2). Graphs
depict densitometry values of COX-2 bands normalized to b-actin
levels. ANOVA P values: P = 0.0116 for WT 74 kDa; P = 0.0030 for
WT 72 kDa; P = 0.0049 for MUT 72 kDa; and P = 0.0005 for MUT
70 kDa; n = 3 for 3-day data; n = 2 for 4- and 5-day data. C, non-
transfected control cells; WT, cells transfected with the wild-type
COX-2 gene; MUT, cells transfected with the mutant gene.3. Results and discussion
3.1. Mutagenesis of glycosylation site Asn580 aﬀects glycoform
expression
By replacing asparagine (Asn) with glutamine (Gln) at resi-
due 580 of the human COX-2 gene, we eﬀectively eliminated
glycosylation at that site (Fig. 1A). As a result, COS-1 cells
transfected with the mutant gene were able to express the 72
but not the 74 kDa glycoform found in cells expressing the
wild-type gene. The mutation also resulted in the expression
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formation is as yet unknown. Fig. 1A shows a signiﬁcantly
large accumulation of both the 70 and the 72 kDa proteins.
In short, removal of the glycosylation site appeared to increase
total COX-2 protein levels. To conﬁrm this, a timecourse
experiment was conducted in which expression patterns of
the glycoforms were analyzed 3, 4, and 5 days after transient
transfection with either the wild-type or mutant COX-2 gene
(Fig. 1B). The concentrations of the two glycoforms expressed
from the mutant gene continued to be greater than those
expressed from the wild-type gene, even as total COX-2
expression started to wane by Day 5. This veriﬁed that removal
of the Asn580 glycosylation site slowed down the turnover of
the COX-2 protein.Fig. 3. Eﬀect of arachidonic and octanoic acid on COX-2 protein
expression. Three days after transient transfection of COS-1 cells with
either the wild-type (WT) or mutant (MUT) COX-2 gene, cells were
treated with 5 lg/ml of arachidonic acid (AA) or octanoic acid (OA)
for 2 h at 37 C. Whole cell lysates were then analyzed via Western
blotting, each lane loaded with 10 lg of protein. Blot shown is
representative of triplicate samples (n = 3). Graph depicts densitometry
values of COX-2 bands normalized to b-actin levels. No statistically
signiﬁcant diﬀerences were found between non-treated (1), AA-treated
(2), or OA-treated (3) samples for either the WT or MUT groups;
n = 3.3.2. Eﬀect of glycosylation on total COX-2 activity
To determine if the accumulation of COX-2 in cells express-
ing the mutant gene also resulted in an increase in total COX-2
activity, levels of the downstream end-product PGE2 were
measured (Fig. 2). Cells carrying either the wild-type (WT)
or mutant (MUT) COX-2 gene were treated with the COX-2
substrate AA for 2 h. PGE2, released by cells into the media,
was measured using an ELISA. As Fig. 2 shows, AA-treated
cells expressing the 70/72 kDa glycoforms had the greatest
PGE2 levels – ﬁve times greater than the levels found in AA-
treated cells expressing the 72/74 kDa glycoforms. PGE2 was
also measured in untreated cells and in cells treated with the
non-substrate fatty acid, OA. As expected, PGE2 levels were
extremely low in the untreated and OA-treated cell groups,
and there were no signiﬁcant diﬀerences between the two
groups.3.3. Eﬀect of AA on COX-2 glycoform expression
Although the presence of AA can lead to an increase in
COX-2 by indirectly up-regulating its transcription [15,26],
the mutant and wild-type COX-2 gene constructs used in this
study were under the control of the pcDNA3 plasmid’s
CMV promoter rather than their native COX-2 promoter.
Thus, the increased COX-2 activity in AA-treated cells (shown
in Fig. 2) was not due to an increase in COX-2 production.Neg. Control
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Fig. 2. Comparing activities of COX-2 glycoforms in the presence of
AA or OA. Three days after transient transfection of COS-1 cells
with either the wild-type (72/74 kDa) or mutant (70/72 kDa) COX-2
gene, cells were treated with 5 lg/ml of arachidonic acid (AA) or
octanoic acid (OA) for 2 h at 37 C. Media was then analyzed for
PGE2 using an ELISA. Neg. Control, non-transfected cells. Data are
represented as average ± S.E.M. *P < 0.05 compared to other two
‘‘AA-treated’’ groups; **P < 0.001 compared to other two ‘‘72/
74 kDa’’ groups; n = 3.However, to conﬁrm that AA treatment had no eﬀect on
COX-2 protein synthesis, a Western blot was carried out on
the same treatment groups described in Fig. 2. Fig. 3 shows
that AA-treated cells produced the same level of COX-2 pro-
tein as control cells (i.e. untreated and OA-treated cells).3.4. Conclusion
A few past studies have examined the glycosylation of COX-
2, but none succeeded in determining the signiﬁcance or pur-
pose of the two COX-2 glycoforms. Though researchers found
glycosylation of COX-2 at Asn53, Asn130, and Asn396 necessary
for proper folding of COX-2 into an active, 72 kDa enzyme
[23], no such function was found for the glycosylation site
Asn580. Ours is the ﬁrst study to describe a biologically signif-
icant role for the glycosylation of Asn580 in the COX-2 protein.
Additionally, our study introduces a new regulatory mecha-
nism for COX-2 expression. Regulation of COX-2 at the levels
of transcription (reviewed in [27]) and post-transcription (i.e.
mRNA stability) [28,29] has already been well-established. In
fact, we previously demonstrated that AA regulates COX-2
transcription via a feed-forward mechanism in prostate cancer
[15,26], most likely mediated by the EP4 prostaglandin recep-
tor [30] and by activation of phosphatidylinositol 3-kinase
(PI3K) [16]. However, regulation after protein synthesis
appeared to be limited to the addition of exogenous COX-2
enzyme inhibitors (e.g. non-steroidal anti-inﬂammatory drugs
(NSAIDs)) [1]. As our study indicates, removal of glycosyla-
tion site Asn580 in the human COX-2 protein leads to an
increase in total COX-2 activity (as reﬂected by a ﬁve-fold in-
crease in PGE2) and an accumulation of both the 72 kDa and
70 kDa COX-2 glycoforms. Although the structure and activ-
ity level of the 70 kDa protein have yet to be determined, it is
entirely possible that this glycoform contributed signiﬁcantly
6536 M.B. Sevigny et al. / FEBS Letters 580 (2006) 6533–6536to the overall increase in COX-2 activity found in the Asn580-
mutant cells. All these data suggest that normal turnover of
COX-2 requires the conversion of the 72 kDa protein into
the 74 kDa glycoform via glycosylation, indicating that regula-
tion of COX-2 can also occur at the post-translational level.
This ﬁnding may be particularly important from a therapeutic
perspective since increased levels of COX-2 protein have been
implicated in various pathological conditions, and glycosyla-
tion of COX-2 appears to be involved with controlling those
levels.
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